Literature DB >> 12090751

Exercise-related syncope in young competitive athletes without evidence of structural heart disease. Clinical presentation and long-term outcome.

F Colivicchi1, F Ammirati, A Biffi, L Verdile, A Pelliccia, M Santini.   

Abstract

AIMS: Exercise-related syncopal spells in athletes receive great attention and are a source of anxiety in the sporting world. The aim of the present study is to describe the clinical presentation, the yield of the initial diagnostic work-up and the long-term outcome of a series of consecutive competitive athletes with recurrent exercise-related syncopal spells. METHODS AND
RESULTS: The study cohort included 33 athletes (20 females, mean age 21.4+/-3.2 years) referred for recurrent unexplained episodes of exercise-related syncope (mean number of spells before evaluation 4.66+/-1.97). All athletes underwent an extensive evaluation, including echocardiography, 24-h electrocardiographic monitoring, exercise testing, cardiac electrophysiological study and head-up tilt testing. The echocardiographic examination revealed the presence of a mitral valve prolapse in two cases (6.0%). During maximal exercise testing, four athletes (12.1%) developed hypotension associated with pre-syncope. Twenty-two subjects (66.6%) showed a positive response to head-up tilt testing. During follow-up (33.5+/-17.2 months) 11/33 athletes (33.3%) showed at least one recurrence of exercise-related syncope (mean time to first recurrence 20.4+/-14.5 months). No other adverse event of any kind was noted during follow-up. The Kaplan-Meier estimates of first recurrence of exercise-related syncope after 12, 36 and 60 months were 9.1%, 24.4% and 42.9%. The number and frequency of exercise-related syncopal spells before evaluation were found to be univariate predictors of syncope recurrence (P<0.001). However, in the multivariate analysis, the number of exercise-related syncopal spells before evaluation was found to be the only independent predictor of syncope recurrence (P<0.05).
CONCLUSIONS: These findings support the idea that recurrent exercise related-syncope is not associated with an adverse outcome in athletes without cardiac disease. Copyright 2002 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12090751     DOI: 10.1053/euhj.2001.3042

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  6 in total

1.  Syncope due to Brugada syndrome in a young athlete.

Authors:  Hans D Esperer; Olaf Hoos; Kuno Hottenrott
Journal:  Br J Sports Med       Date:  2006-11-30       Impact factor: 13.800

2.  2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.

Authors:  Robert S Sheldon; Blair P Grubb; Brian Olshansky; Win-Kuang Shen; Hugh Calkins; Michele Brignole; Satish R Raj; Andrew D Krahn; Carlos A Morillo; Julian M Stewart; Richard Sutton; Paola Sandroni; Karen J Friday; Denise Tessariol Hachul; Mitchell I Cohen; Dennis H Lau; Kenneth A Mayuga; Jeffrey P Moak; Roopinder K Sandhu; Khalil Kanjwal
Journal:  Heart Rhythm       Date:  2015-05-14       Impact factor: 6.343

Review 3.  Orthostatic Circulatory Disorders: From Nosology to Nuts and Bolts.

Authors:  Michael Gutkin; Julian M Stewart
Journal:  Am J Hypertens       Date:  2016-04-01       Impact factor: 2.689

Review 4.  Exercise related syncope, when it's not the heart.

Authors:  C T Paul Krediet; Arthur A M Wilde; Wouter Wieling; John R Halliwill
Journal:  Clin Auton Res       Date:  2004-10       Impact factor: 4.435

5.  Association Between Baseline Blood Pressures, Heart Rates, and Vasovagal Syncope in Children and Adolescents.

Authors:  Himanshu Adlakha; Ruchi Gupta; Romana Hassan; Jeffrey H Kern
Journal:  Cureus       Date:  2018-01-28

Review 6.  Common syndromes of orthostatic intolerance.

Authors:  Julian M Stewart
Journal:  Pediatrics       Date:  2013-04-08       Impact factor: 7.124

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.